HIF1A and breast carcinoma: Cryptolepine prevented HIF-1-mediated glycolysis and reduced the production of several glycolytic enzymes in T47D and 4T1 breast cancer cells by suppressing HIF-1 transcriptional activity and decreasing hypoxia-induced HIF-1α protein expression, resulting in decreased ATP production in tumor cells.